Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Cinrebafusp alfa (PRS 343) is an anticalin-based bispecific drug with high affinity for both CD137/HER2, displaying dissociation constants (Kd) of 0.3 nM to recombinant human HER2 and 5 nM to human monomeric CD137 (4-1BB). It promotes T-cell costimulation via tumor-localized, HER2-mediated 4-1BB clustering and activation, thereby enhancing T-cell receptor-driven responses and facilitating tumor cell eradication. This compound shows promising potential in research concerning HER2-positive solid tumors [1] [2]. |
In vitro | Cinrebafusp alfa (PRS 343) binds to HER2-expressing MCF-7 cells and CHO cells transfected with human 4-1BB, exhibiting EC50 values of 7.4 nmol/L and 6.2 nmol/L, respectively, as determined by FACS analysis [1]. |
In vivo | Cinrebafusp alfa (PRS 343; 0.2-10 mg/kg; intravenous administration; once a week; 20 days) showed dose-dependent tumor growth inhibition and increased tumor-infiltrating lymphocytes in a humanized mouse model transplanted with HER2-positive SK-OV-3 tumor cells [1]. In male CD-1 mice, the terminal elimination half-life of Cinrebafusp alfa (10 mg/kg; intravenous administration; single dose) was more than 14 days. In male cynomolgus monkeys, the terminal elimination half-life of Cinrebafusp alfa (3 mg/kg; intravenous injection; single dose) was approximately 4 days [1]. |
Alias | PRS 343 |
Cas No. | 2218515-90-1 |
Storage |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.